• Explore /
  • Poster
  • / NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring <em>EGFR</em> mutations (EGFRm).

NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).

Abstract Video & Slides Poster

Authors

Naoki Furuya

Naoki Furuya

Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, OH, Japan

Naoki Furuya , Satoshi Watanabe , Atsushi Nakamura , Jun Shiihara , Ichiro Nakachi , Hisashi Tanaka , Mika Nakao , Koichi Minato , Masahiro Seike , Shinichi Sasaki , Akira Kisohara , Susumu Takeuchi , Ryoichi Honda , Kei Takamura , Hiroshi Kagamu , Kenichi Yoshimura , Toshiaki Kikuchi , Kunihiko Kobayashi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

031190066

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9110)

DOI

10.1200/JCO.2022.40.16_suppl.9110

Abstract #

9110

Poster Bd #

96

Abstract Disclosures

Similar Posters

First Author: Satoshi Watanabe

First Author: Dale Randall Shepard

First Author: Rana R. McKay

First Author: Vassiliki Papadimitrakopoulou